{
    "2019-03-01": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Pharma Stock Roundup: Roche to Buy ONCE, Lawmakers Grill CEOs Over High Drug Prices",
                "features": {
                    "keywords": [
                        "Roche",
                        "Buy",
                        "ONCE",
                        "Lawmakers",
                        "Grill",
                        "CEOs",
                        "High Drug Prices"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-03-14",
                "original_text": "AbbVie to Present at the Barclays Global Healthcare Conference",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Present",
                        "Barclays",
                        "Global Healthcare Conference"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-03-16",
                "original_text": "AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI™) for the Treatment of Moderate to Severe Plaque Psoriasis",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "CHMP",
                        "Positive Opinion",
                        "Risankizumab",
                        "SKYRIZI™",
                        "Moderate to Severe Plaque Psoriasis"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}